We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Adagene Inc. Sponsored ADR (ADAG - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adagene Inc. Sponsored ADR is one of 1111 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adagene Inc. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADAG's full-year earnings has moved 57.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, ADAG has gained about 2.3% so far this year. Meanwhile, stocks in the Medical group have lost about 2.9% on average. As we can see, Adagene Inc. Sponsored ADR is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Alcon (ALC - Free Report) . The stock has returned 18.8% year-to-date.
For Alcon, the consensus EPS estimate for the current year has increased 4.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adagene Inc. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 533 individual stocks and currently sits at #94 in the Zacks Industry Rank. On average, stocks in this group have lost 13.1% this year, meaning that ADAG is performing better in terms of year-to-date returns.
In contrast, Alcon falls under the Medical - Instruments industry. Currently, this industry has 95 stocks and is ranked #107. Since the beginning of the year, the industry has moved +4.1%.
Investors interested in the Medical sector may want to keep a close eye on Adagene Inc. Sponsored ADR and Alcon as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Adagene Inc. Sponsored ADR (ADAG - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adagene Inc. Sponsored ADR is one of 1111 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adagene Inc. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADAG's full-year earnings has moved 57.1% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, ADAG has gained about 2.3% so far this year. Meanwhile, stocks in the Medical group have lost about 2.9% on average. As we can see, Adagene Inc. Sponsored ADR is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Alcon (ALC - Free Report) . The stock has returned 18.8% year-to-date.
For Alcon, the consensus EPS estimate for the current year has increased 4.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adagene Inc. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 533 individual stocks and currently sits at #94 in the Zacks Industry Rank. On average, stocks in this group have lost 13.1% this year, meaning that ADAG is performing better in terms of year-to-date returns.
In contrast, Alcon falls under the Medical - Instruments industry. Currently, this industry has 95 stocks and is ranked #107. Since the beginning of the year, the industry has moved +4.1%.
Investors interested in the Medical sector may want to keep a close eye on Adagene Inc. Sponsored ADR and Alcon as they attempt to continue their solid performance.